Symbols

ABCL

AbCellera Biologics·NASDAQ

--(--)

ABCL Profile

Abcellera Biologics Inc.

A Canadian provider of drug discovery platform that designed to develop next-generation antibody therapies

Industry

Biological Technology

Established Date

11/08/2012

Listing Date

12/11/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

562

Fiscal Year Ends

12-31

Website

www.abcellera.com

Security Type

Common stock

Office address

150 W 4th Avenue, Vancouver, BC V5Y 1G6

Business

Introduction

AbCellera Biologics Inc., was incorporated and commenced business activities on November 8, 2012 under the British Columbia Business Companies Act. The company is a clinical-stage biotechnology company focused on discovering and developing best-in-class antibody drugs for high unmet medical needs. The company has established a platform to advance antibody drug projects, which they believe provides them with a competitive advantage in addressing challenging high-value targets such as complex transmembrane proteins and new models including multispecific and antibody-drug conjugates.